Pulmonary-renal syndromes

Acta Clinica Belgica

Volumn 62, Issue 2, 2007, Pages 88-96

  Brusselle, Guy G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Diffuse alveolar haemorrhage; Glomerulonephritis; Goodpasture's syndrome; Pulmonary renal syndromes; Vasculitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; STEROID;

ANCA ASSOCIATED VASCULITIS; BLADDER CARCINOMA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LUNG DISEASE; LUNG HEMORRHAGE; LUNG KIDNEY SYNDROME; LUNG LAVAGE; MICROSCOPIC POLYANGIITIS; MYELODYSPLASTIC SYNDROME; PLASMAPHERESIS; PLEURA DISEASE; PNEUMOCYSTIS PNEUMONIA; RADIODIAGNOSIS; REVIEW; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; WEGENER GRANULOMATOSIS;

EID: 34248212678     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.016     Document Type: Review

References (56)

1. Niles JL et al. The syndrome of lung haemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 1996; 156(4): 440-5.
2. Couser WG. Glomerulonephritis. Lancet 1999; 353(9163): 1509-15.
3. Bolton WK. Rapidly progressive glomerulonephritis. Semin Nephrol 1996; 16(6): 517-26.
4. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368(9533): 404-18.
5. Savige J et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999; 111(4): 507-13.
6. Devaney KO et al. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14(6): 555-64.
7. Hoffman GS et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116(6): 488-98.
8. Anderson G et al. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 1992; 83(302): 427-38.
9. Cotch MF et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996; 39(1): 87-92.
10. Watts RA et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000; 43(2): 414-9.
11. Leavitt RY et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33(8): 1101-7.
12. Haworth SJ et al. Pulmonary haemorrhage complicating Wegener's granulomatosis and microscopic polyarteritis. Br Med J (Clin Res Ed) 1985; 290(6484): 1775-8.
13. Travis WD, Carpenter HA, Lie JT. Diffuse pulmonary haemorrhage. An uncommon manifestation of Wegener's granulomatosis. Am J Surg Pathol 1987; 11(9): 702-8.
14. Travis WD et al. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991; 15(4): 315-33.
15. Gaudin PB et al. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. Am J Clin Pathol 1995; 104(1): 7-16.
16. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318(25): 1651-7.
17. Jennette JC, Hoidal JR, Falk RJ. Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood 1990; 75(11): 2263-4.
18. Frankel SK et al. Update in the diagnosis and management of pulmonary vasculitis. Chest 2006; 129(2): 452-65.
19. Fauci AS et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98(1): 76-85.
20. Jayne D et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. N Engl J Med 2003; 349(1): 36-44.
21. Lockwood CM et al. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J 1975; 2(5965): 252-4.
22. Lockwood CM et al. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet 1976; 1(7962): 711-5.
23. Klemmer PJ et al. Plasmapheresis therapy for diffuse alveolar haemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42(6): 1149-53.
24. Pusey CD et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40(4): 757-63.
25. Gaskin G, Pusey CD. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher 2001; 5(3): 176-81.
26. Frasca GM et al. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. Ther Apher Dial 2003; 7(6): 540-6.
27. Luqmani RA et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Qjm 1994; 87(11): 671-8.
28. Stone JH et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44(4): 912-20.
29. Jennette JC et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37(2): 187-92.
30. Guillevin L et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42(3): 421-30.
31. Akikusa B et al. Necrotizing alveolar capillaritis in autopsy cases of microscopic polyangiitis. Incidence, histopathogenesis, and relationship with systemic vasculitis. Arch Pathol Lab Med 1997; 121(2): 144-9.
32. Gayraud M et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44(3): 666-75.
33. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361(9357): 587-94.
34. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32(1): 45-53.
35. Duncan MD, Wilkes DS.Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proc Am Thorac Soc 2005; 2(5): 449-55.
36. Seo P et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005; 52(7): 2168-78.
37. Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture's syndrome. South Med J 2002; 95(12): 1411-8.
38. McPhaul JJ, Mullins JD. Glomerulonephritis mediated by antibody to glomerular basement membrane. Immunological, clinical, and histopathological characteristics. J Clin Invest 1976; 57(2): 351-61.
39. Martinez JS, Kohler PF. Variant "Goodpasture's syndrome"? The need for immunologic criteria in rapidly progressive glomerulonephritis and haemorrhagic pneumonitis. Ann Intern Med 1971; 75(1): 67-76.
40. Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis J Am Soc Nephrol 1999; 10(6): 1389-404.
41. Jones JG et al. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980; 1(8159): 66-8.
42. Wilson CB, Smith RC. Goodpasture's syndrome associated with influenza A2 virus infection. Ann Intern Med 1972; 76(1): 91-4.
43. Holdsworth S et al.The clinical spectrum of acute glomerulonephritis and lung haemorrhage (Goodpasture's syndrome). Q J Med 1985; 55(216): 75-86.
44. Keogh AM et al. Exacerbation of Goodpasture's syndrome after inadvertent exposure to hydrocarbon fumes. Br Med J (Clin Res Ed) 1984; 288(6412): 188.
45. Kelly PT, Haponik EF. Goodpasture syndrome: molecular and clinical advances. Medicine (Baltimore) 1994; 73(4): 171-85.
46. Perl SI et al. Goodpasture's (anti-GBM) disease and HLA-DRw2. N Engl J Med 1981; 305(8): 463-4.
47. Rees AJ et al. Strong association between HLA-DRW2 and antibody-mediated Goodpasture's syndrome. Lancet 1978; 1 (8071): 966-8.
48. Rees AJ et al. The influence of HLA-linked genes on the severity of anti-GBM antibody-mediated nephritis. Kidney Int 1984;26(4): 445-50.
49. Sturgill BC, Westervelt FB. Immunofluorescence studies in a case of Goodpasture's syndrome. Jama 1965; 194(8): 914-6.
50. Koffler D et al. Variable patterns of immunoglobulin and complement deposition in the kidneys of patients with systemic lupus erythematosus. Am J Pathol 1969; 56(3): 305-16.
51. Johnson JP et al. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985; 64(4): 219-27.
52. McCormick JR, Kass J, Skewes M. Goodpasture's syndrome. Compr Ther 1987; 13(7): 25-32.
53. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973; 3(2): 74-89.
54. Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119(3): 471-503.
55. Zamora MR et al. Diffuse alveolar haemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997; 76(3): 192-202.
56. Cadman EC, Lundberg WB, Mitchell MS. Pulmonary manifestations in Behcet syndrome. Case report and review of the literature. Arch Intern Med 1976; 136(8): 944-7.